Strumento inattivo

Azioni Juno Therapeutics Inc

Azioni

Durata

Periodo

Stile

Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	29/03/18
Gilead Sciences : Sangamo in $3 billion gene-editing deal with Gilead	22/02/18
Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition	21/02/18

Dirigenti	Titolo	Età	Da
Nicole Keith IRC	Investor Relations Contact	-	01/07/15
Jonathan Biller TRE	Treasurer	61	-
Katherine Reynolds Kelly SEC	Corporate Secretary	48	-

Amministratori	Titolo	Età	Da
Mark Alles BRD	Director/Board Member	64	-
Peter Kellogg BRD	Director/Board Member	67	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,73 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd